Publication details

Analysis of Clinical Phenotypes through Machine Learning of First-Line H. pylori Treatment in Europe during the Period 2013-2022: Data from the European Registry on H. pylori Management (Hp-EuReg)

Authors	NYSSEN Olga PRATESI Pietro SPINOLA Miguel JONAITIS Laimas PEREZ-AISA Angeles VAIRA Dino SARACINO Ilaria Maria PAVONI Matteo FIORINI Giulia TEPES Bojan BORDIN Dmitry VOYNOVAN Irina LANAS Angel MARTINEZ-DOMINGUEZ Samuel ALFARO Enrique BUJANDA Luis PABON-CARRASCO Manuel HERNANDEZ Luis GASBARRINI Antonio KUPCINSKAS Juozas LERANG Frode SMITH Sinead GRIDNYEV Oleksiy LEJA Marcis ROKKAS Theodore MARCOS-PINTO Ricardo MESTROVIC Antonio MARLICZ Wojciech MILIVOJEVIC Vladimir SIMSEK Halis KUNOVSKÝ Lumír PAPP Veronika PHULL Perminder VENERITO Marino BOYANOVA Lyudmila BOLTIN Doron NIV Yaron MATYSIAK-BUDNIK Tamara DOULBERIS Michael DOBRU Daniela LAMY Vincent CAPELLE Lisette TRPCHEVSKA Emilijia Nikolovska MOREIRA Leticia CANO-CATALIA Anna PARRA Pablo MEGRAUD Francis MORAIN Colm ORTEGA Guillermo GISBERT Javier INVESTIGATORS Hp EuReg
Year of publication	2023
Type	Article in Periodical
Magazine / Source	Antibiotics-Basel
MU Faculty or unit	Faculty of Medicine
Citation
Web	https://www.mdpi.com/2079-6382/12/9/1427
Doi	http://dx.doi.org/10.3390/antibiotics12091427
Keywords	Helicobacter pylori; clustering; phenotyping; machine learning; treatment; eradication
Description	The segmentation of patients into homogeneous groups could help to improve eradication therapy effectiveness. Our aim was to determine the most important treatment strategies used in Europe, to evaluate first-line treatment effectiveness according to year and country. Data collection: All first-line empirical treatments registered at AEGREDCap in the European Registry on Helicobacter pylori management (Hp-EuReg) from June 2013 to November 2022. A Boruta method determined the "most important" variables related to treatment effectiveness. Data clustering was performed through multi-correspondence analysis of the resulting six most important variables for every year in the 2013-2022 period. Based on 35,852 patients, the average overall treatment effectiveness increased from 87% in 2013 to 93% in 2022. The lowest effectiveness (80%) was obtained in 2016 in cluster #3 encompassing Slovenia, Lithuania, Latvia, and Russia, treated with 7-day triple therapy with amoxicillin-clarithromycin (92% of cases). The highest effectiveness (95%) was achieved in 2022, mostly in Spain (81%), with the bismuth-quadruple therapy, including the single-capsule (64%) and the concomitant treatment with clarithromycin-amoxicillin-metronidazole/tinidazole (34%) with 10 (69%) and 14 (32%) days. Cluster analysis allowed for the identification of patients in homogeneous treatment groups assessing the effectiveness of different first-line treatments depending on therapy scheme, adherence, country, and prescription year.